Comparative Pharmacology
Head-to-head clinical analysis: IOMERVU versus ISOPAQUE 280.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOMERVU versus ISOPAQUE 280.
IOMERVU vs ISOPAQUE 280
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by increasing radiopacity of blood vessels and tissues, allowing visualization during imaging procedures.
Isopaque 280 (metrizoate) is an ionic, high-osmolar iodinated radiocontrast agent that attenuates X-rays by increasing the density of tissues where it distributes, thereby enhancing vascular and organ visualization during imaging.
Intravenous: 0.5-2 mL/kg of iomeprol 300-400 mg I/mL for imaging, not exceeding 200 mL total dose; arterial: up to 250 mL per procedure.
Iohexol (ISOPAQUE 280) is administered intravenously, intra-arterially, or by other appropriate routes. Typical adult dose for CT imaging: 50–150 mL (concentration 280 mg I/mL) as a bolus or infusion. For angiography: 5–80 mL per injection, depending on procedure. Repeat doses may be given up to a total of 350 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged (up to 10-30 hours in severe impairment), necessitating dose adjustment and monitoring. The half-life is not significantly affected by hepatic impairment.
Terminal elimination half-life is 1.5–2 hours in patients with normal renal function; prolonged to >10 hours in severe renal impairment, requiring dose adjustment.
Iomeprol is almost exclusively eliminated via renal glomerular filtration, with 92-98% of the administered dose recovered unchanged in urine within 24 hours. Less than 2% is excreted in feces via biliary elimination. In patients with normal renal function, renal clearance approximates glomerular filtration rate.
Renal: approximately 95% of the dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Fecal: <5%; biliary excretion is negligible.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent